- Code
- MP0233
- Type
- Master's Degree
- Teaching Modality
- No Face-to-face
- Duration
- 2 years
- Credits
- 60.0
- Course
- 2025-2026
- Price
- 1.300,00€
- Center
- Facultad de Medicina y Odontología
- Management
-
Maximo Francisco Fraga Rodriguez
José María Moraleda Jiménez - Contact
joseluis.bello [at] usc.es
Department / Organizing Center
Ciencias Forenses, Anatomía Patológica, Ginecología y Obstetricia y Pediatría
JOSÉ LUIS BELLO LÓPEZ
619067407
joseluis.bello [at] usc.es
Facultad de Medicina y Odontología
Dates
Duration: 01/11/2025 - 31/05/2027
Pre-registration: 01/09/2025 - 15/09/2025
Registration: 16/09/2025 - 30/09/2025
Minimum number of students: 50
Maximum number of students: 50
Commentaries: Colaboración da Universidade de Santiago, Universidade de Murcia e a Fundación Española de Hematoloxía e Hemoterapia.
Mandatory insurance:
20,69€ (Students who formally enroll in their own Postgraduate courses, Continuous Training and Training Program, will also be included the amount of mandatory accident insurance and travel assistance for USC students, as established in current regulations (Council Agreement Government June 29, 2009) and will be issued together with the 1st liquidation of registration. Except in the courses that are 100% virtuous, considered these by academic year; and in the cases in which the students have paid this same insurance in a USC degree in the current academic year.)
Access requirements
Degree of Medicine, Hematology Specilalists (internship in Hematology, either finished or ongoing). Likewise, other specialists related to the diagnosis and treatment of lymphoid neoplasms may be enrolled.
Pre-registration
You can consult a manual of the admission procedure on the CEP website in Archive or by clicking here
To apply for admission, go to the following link of the virtual secretary
https://matricula.usc.es/Posgrao/SolicitudeEstudosPropios
Access to pre-registration and registration
Selection system
Admission will be made according to the general criteria indicated: -20% Academic record. -50% being professional in the area of the masters’ profile. -30% Studies and research in the area of lymphoid neoplasms.
Objectives
- To provide a global perspective of lymphoid neoplastic pathologies.- To enable a thorough knowledge of the new diagnostic techniques.
- To acquire knowledge of the current & future lines of treatment: mutation-oriented drugs, innovative immunological therapies with mono or bispecific monoclonal antibodies and cell therapy (i.e., T-CAR or NK-CAR).
- To provide students of the basic knowledge to open new fields of research in the main pathologies of the lymphoproliferative disorders.
Career options
The Masters is composed of 4 teaching modules or units, which will be accessed progressively as the previous one is passed. The duration is 19 months. The format will be 100% online, and it will be available on a permanent basis, so that students can organize themselves properly to develop the Masters at the pace that best suits their possibilities.The student will have access to the course material through an individual password. The theory lectures will last 30 minutes, and they will be taught by a member of the teaching staff. This class will be available on video, ir oder to be watched at any time and as often as the student needs. They will also have a scheme of information synthesized and presented graphically and interactively, as well as an original document of the module that will compile its theoretical contents. There will be complementary practical activities based on scenarios drawn from real situations of clinical practice. As additional resources, students will have an image gallery, downloadable templates, links of interest, etc. They will also have schematic summary videos of the most notable aspects of each module to consolidate learning. They will have a written communication channel at the group level, included in the e-learning platform. Finally, there will be a direct and private written communication channel between the student and the tutors.
The student will take a self-assessment test at the beginning of each module to assess the level of prior knowledge. A new test will be carried out, once the corresponding module has been completed, to assess the level of knowledge reached and which will serve as a score for the final mark.
Students will also write a masters’ thesis. The evaluation of the thesis will be carried out by the teachers and tutors of each module together with the academic commission.
Evaluation
The knowledge acquired by the student will be continuously evaluated. Students will be monitored throughout the course, evaluating active participation in tutorials and discussion forums. In addition, there will be a written test at the end of each of the 4 modules to assess the level of comprehension of the acquired knowledge, which will be an additional mark to take into account for the final evaluation. Students will also make a masters’ thesis. The evaluation of the thesis will be carried out by the teachers of each module, tutors and the academic committee.
Tutoring
Coordinators and tutors will be assigned to each Module (4 coordinators, 4 tutors), and these will be responsible (along with the Masters’ Directors) for reviewing and evaluating the documentation of each subject conducted by the teachers, as well as the evaluation questions. These coordinators and tutors will guide the students along their corresponding module and will lead the discussion forum. The student must download the topics of each Module in order to study, evaluate and make comments on them, as well as to solve the questions with support of their tutor. Discussion forums will be held to strengthen knowledge.
Formación on line continuada
Observations
Colaboración da Universidade de Santiago, Universidade de Murcia e a Fundación Española de Hematoloxía e Hemoterapia.
| Code | Subject | Credits |
|---|---|---|
| 1 | Molecular Pathogenesis Of Lymphoproliferative Lesions. Molecular Basis Of Treatment (Personalized Therapy). | 5.0 |
| 2 | Diagnosis And Classification. | 1.5 |
| 3 | Staging. Response Criteria. Geriatric Scales. | 1.5 |
| 4 | Hodgkin's Lymphoma. First-Line Treatment. Long-Term Follow-Up. | 4.5 |
| 5 | Treatment Of Patients With Relapsed Or Refractory Hodgkin Lymphoma. | 1.5 |
| 6 | Epidemiology. Clinical Presentation, Diagnosis And PretreatmENT evaluation: Staging And PrognosTIC Classification. | 2.0 |
| 7 | Indolent Lymphomas. Follicular Lymphoma. | 5.0 |
| 8 | Indolent Lymphomas. Marginal Zone Lymphomas. | 1.5 |
| 9 | Indolent Lymphomas. Waldenström Macroglobulinemia. | 1.5 |
| 10 | T-Cell LymphoblasTIC Leukemia/lymphoma. Leukemic T-Cell Lymphomas. (22nd Year) | 1.5 |
| 11 | Nodal T Lymphomas. Extranodal T-Cell Lymphomas. (22nd Year) | 2.0 |
| 12 | Cutaneous Lymphomas: Mycosis Fungoides-Sézary Syndrome. Other Cutaneous Lymphomas. (22nd Year) | 1.5 |
| 13 | T-Cell And Nk-Cell Lymphoid Neoplasms. (22nd Year) | 3.0 |
| 14 | Master's Thesis. (22nd Year) | 6.0 |
| 15 | Chronic B-Cell Lymphoproliferative Syndromes With Leukemic Expression. (22nd Year) | 3.0 |
| 16 | Aggressive-B-Cell Lymphomas. Mantle Cell Lymphoma. (22nd Year) | 1.5 |
| 17 | Aggressive B- Cell Lymphomas. Diffuse Large B-Cell Lymphoma (Dlbcl) Not Otrerwise Specified. Other Types. (22nd Year) | 5.5 |
| 18 | Aggressive B-Cell Lymphomas. PlasmablasTIC Spectrum Lymphomas: PlasmablasTIC Lymphoma, Primary Effusion Lymphoma, Alk + Large B-Cell Lymphoma, Hhv8 + Large B-Cell Lymphomas. (22nd Year) | 1.5 |
| 19 | Aggressive B-Cell Lymphomas. Mediastinal Lymphomas (Primary Mediastinal Lymphoma And Grey Zone Lymphoma). Lymphomas Of Immunoprivileged Sites (Primary Brain, Primary Testicular). (22nd Year) | 1.5 |
| 20 | Aggressive B-Cell Lymphomas. Burkitt Lymphoma. B Lymphoma/lymphoblasTIC Leukemia. (22nd Year) | 1.5 |
| 21 | Aggressive B-Cell Lymphomas. Lymphoproliferative Disorders Associated With Immunodeficiency. (22nd Year) | 1.5 |
| 22 | Chronic B-Cell Lymphoproliferative Syndromes With Leukemic Expression. Diagnosis And Molecular Profile. (22nd Year) | 1.5 |
| 23 | Chronic B-Cell Lymphoproliferative Syndromes With Leukemic Expression. Frontline Treatment Of Chronic LymphocyTIC Leukemia (Cll). (22nd Year) | 1.5 |
| 24 | Chronic B-Cell Lymphoproliferative Syndromes With Leukemic Expression. Salvage Treatment In Chronic LymphocyTIC Leukemia (Cll). (22nd Year) | 1.5 |
| 25 | Chronic B-Cell Lymphoproliferative Syndromes With Leukemic Expression. ProlymphocyTIC Leukemia. Hairy Cell Leukemia. (22nd Year) | 1.5 |